Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics

Current Blockbusters, New Products To Make Up Difference

Executive Summary

Bristol executives reiterated the company’s aggressive revenue growth expectations while outlining the impact Revlimid generics will have in Europe, Japan and – to a limited extent – in the US.

You may also be interested in...



Q4 Earnings Preview: It's All About Growth Goals And Deal Plans (Part 2)

Industry's big players report fourth quarter results over the next two weeks. Updates on leadership changes, growth targets and deal plans are among the hot topics.

Cipla Remains Upbeat On Abraxane As US Generic Competition Looms

Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.

Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition

Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel